You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
再鼎醫藥(09688.HK):一季度產品收入8710萬美元 同比增長39%

格隆匯5月9日丨再鼎醫藥(09688.HK)公佈2024年第一季度財務業績,2024年第一季度產品收入為8,710萬美元,2023年同期為6,280萬美元,同比增長39%,按CER計算同比增長43%。產品收入增加主要是由於包括去年9月衞偉迦上市在內的銷量增加,以及部分產品因納入中國國家醫保藥品目錄(NRDL)而降價導致給予經銷商的銷售返利減少。2024年第一季度的研發開支為5,460萬美元,2023年同期為4,850萬美元。這一增長主要是由於新啟動和正在開展的臨牀研究的費用的增加,部分被許可產品的里程碑款項的減少所抵銷。

根據披露,則樂® :2024年第一季度銷售收入為4,550萬美元,2023年同期為4,270萬美元,同比增長7%,這主要是由於卵巢癌一線維持治療院內銷售的增加、治療持續時間的增加以及則樂用於成人一線卵巢癌和鉑敏感復發卵巢癌維持治療的適應證成功續約NRDL並於2024年1月1日生效。

衞偉迦® :2024年第一季度銷售收入為1,320萬美元,2023年同期未產生收入,這主要是由於醫生和患者的積極反饋以及隨着衞偉迦進院而增加的患者可及性。衞偉迦2023年9月成功上市,用於治療全身型重症肌無力(gMG),隨後被首次納入 NRDL,並於2024年1月1日生效。此外,擎樂® :2024年第一季度銷售收入為610萬美元,2023年同期為130萬美元,同比增長367%;紐再樂® :2024年第一季度銷售收入為990萬美元,2023年同期為550萬美元,同比增長81%。

再鼎醫藥創始人、董事長兼首席執行官杜瑩博士表示:“第一季度的業績展現了我們具有同類首創和同類最優潛力的產品組合在商業化執行和管線研發方面的強勁進展。衞偉迦在第一季度顯現出良好的開局,銷售額達到1,320萬美元。展望未來,我們預計將在今年接下來的時間加速商業化工作,為2024年三個新的潛在產品上市做好準備。我們也為再鼎處於後期的管線進展感到興奮,我們正在順利推進五年戰略規劃中設定的各項目標,包括收入顯著增長和2025年底實現盈利。”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account